REported Outcomes in COPD With Trixeo in Real worlD in Germany
NCT ID: NCT05311306
Last Updated: 2025-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
475 participants
OBSERVATIONAL
2022-03-15
2024-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The RECORD study is a prospective, non-interventional study to be conducted in the United Kingdom (UK) and Germany. The study aims to generate data to describe the real world effectiveness of TRIXEO for patients with COPD who receive TRIXEO in routine clinical practice. It also aims describe patients HRQoL, physical activity and treatment satisfaction, and will explore patients' sleep quality and adherence to inhalers in the real-world. This data may provide important information for practicing physicians.
The study will include approximately 500 patients with moderate to severe COPD from approximately 50 sites (including hospitals and GP practices) in Germany. Patients eligible for TRIXEO therapy may be enrolled by their treating physicians. The decision to treat with TRIXEO must be independent of the study and made by the treating physician according to the patients' medical need and local routine clinical practice. Patients' data will be collected for 12 months after starting therapy with TRIXEO.
Demographic and clinical data will be extracted from patients' health care records. Patient reported outcomes will be collected remotely by asking patients to answer questionnaires on health status and HRQoL, physical activity, sleep quality, treatment satisfaction, and inhaled medication adherence through electronic surveys.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
REported Outcomes in COPD With Trixeo in Real worlD
NCT05213611
Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
NCT05915182
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.
NCT06321731
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
NCT06368427
Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
NCT05862545
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having been prescribed treatment with TRIXEO according to label and local market reimbursement criteria
* Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol
* After full explanation, patients must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.
Exclusion Criteria
* Previous treatment with any other triple fixed-dose combination during screening
* Hospitalisation due to COPD exacerbation within the last 4 weeks prior to enrolment
* Pregnancy or lactation period
* Participation in an observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in a randomised clinical trial in the last 30 days.
* Patient still recovering from Covid-19 infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Böblingen, Germany, Germany
Research Site
Doerfles-Esbach, Germany, Germany
Research Site
Fürstenwalde, Germany, Germany
Research Site
Marburrg, Germany, Germany
Research Site
Auerbach, , Germany
Research Site
Augsburg, , Germany
Research Site
Bad Neustadt A.d. Saale, , Germany
Research Site
Bayreuth, , Germany
Research Site
Beelitz, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Biberach, , Germany
Research Site
Bremen, , Germany
Research Site
Bremen, , Germany
Research Site
Cottbus, , Germany
Research Site
Darmstadt, , Germany
Research Site
Dresden, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Echterdingen, , Germany
Research Site
Ehringshausen, , Germany
Research Site
Filderstadt, , Germany
Research Site
Flensburg, , Germany
Research Site
Frankfurt, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Fürth, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Hattingen, , Germany
Research Site
Ibbenbueren, , Germany
Research Site
Kronach, , Germany
Research Site
Laage, , Germany
Research Site
Leipzig, , Germany
Research Site
Marburg, , Germany
Research Site
Markkleeberg, , Germany
Research Site
Nuremberg, , Germany
Research Site
Nuremberg, , Germany
Research Site
Nuremberg, , Germany
Research Site
Peißenberg, , Germany
Research Site
Potsdam, , Germany
Research Site
Potsdam, , Germany
Research Site
Rathenow, , Germany
Research Site
Rendsburg, , Germany
Research Site
Rosenheim, , Germany
Research Site
Rostock, , Germany
Research Site
Roth, , Germany
Research Site
Saalfeld, , Germany
Research Site
Saarlouis, , Germany
Research Site
Schleswig, , Germany
Research Site
Teuchern, , Germany
Research Site
Treuchtlingen, , Germany
Research Site
Ulm, , Germany
Research Site
Weißenburg, , Germany
Research Site
Wiesbaden, , Germany
Research Site
Wilhelmshaven, , Germany
Research Site
Witten, , Germany
Research Site
Würzburg, , Germany
Research Site
Zirndorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5980R00037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.